Mar 31, 2020
Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity
Sep 20, 2019
FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
Jun 17, 2019
FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years
May 22, 2019
Novo Nordisk to present data on oral semaglutide at the 79th Annual American Diabetes Association Scientific Sessions
Apr 28, 2019
Victoza® demonstrated superiority in reducing blood sugar vs placebo in children and adolescents with type 2 diabetes
Mar 21, 2019
North America Glucagon like Peptide - 1 Agonists Market 2019-2024 by Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide) & Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Mar 20, 2019
Novo Nordisk files for US FDA approval of oral semaglutide for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes
Jun 24, 2018
Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW
Jun 24, 2018
Adding Liraglutide to Insulin Regimen for People with Type 1 Diabetes Improved Glycemic Control
Jun 23, 2018
Significant blood sugar improvement with Xultophy® 100/3.6 compared to insulin glargine U-100 when used as add-on to oral diabetes medications
Apr 18, 2018
Xultophy® approved in Canada for the treatment of adults with type 2 diabetes
Mar 19, 2018
Semaglutide injection phase 2 data presented at ENDO demonstrated significant weight loss in adults with obesity
Dec 08, 2017
Prime Therapeutics Signs Outcomes-Based Contract with Novo Nordisk for Type 2 Diabetes Drug Victoza® (liraglutide)
Nov 21, 2017
Health Canada approves Victoza® as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.
Sep 15, 2017
New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes
Sep 06, 2017
Berg & Androphy: $46.5M Settlement in False Claims Act Case Over Alleged Illegal Marketing of Novo Nordisk Diabetes Drug Victoza
Sep 05, 2017
Novo Nordisk announces conclusion of U.S. federal investigation of marketing practices
Aug 25, 2017
Victoza® (liraglutide) is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events
Jun 20, 2017
Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes
Jun 10, 2017
Xultophy® 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy